SkinBioTherapeutics plc (AIM:SBTX)

Market Cap	52.43M +29.3%
Revenue (ttm)	4.64M +283.7%
Net Income	-696.25K
EPS	-0.00
Shares Out	258.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	487,121
Average Volume	1,241,444
Open	20.67
Previous Close	21.00
Day's Range	20.06 - 21.50
52-Week Range	12.00 - 27.50
Beta	0.73
RSI	57.92
Earnings Date	Mar 25, 2026

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 41
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SBTX

Financial Performance

In fiscal year 2025, SkinBioTherapeutics's revenue was 4.64 million, an increase of 283.74% compared to the previous year's 1.21 million. Losses were -696,253, -75.79% less than in 2024.